Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTERA: ALT-L9 versus Eylea in neovascular age-related macular degeneration
jRCT2071210144Phase 3Completed
- Sponsor
- Altos Biologics
- Start
- Jun 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of alt-l9 in exudative macular degeneration (2 arms), sponsored by Altos Biologics. Primary endpoint: Change from baseline in BCVA at Week 8. Started Jun 2022; status: completed.
02
Drugs
alt-l9
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2071210144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210144.